Literature DB >> 9045619

Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene.

H Chen1, M C Hung.   

Abstract

Overexpression of HER-2/neu is frequently found in human cancer and has been shown to enhance the metastatic potential of tumors and to induce the chemoresistance of cancer cells. The molecular mechanism(s) by which HER-2/neu expression is deregulated in cancer is not clear. We reported previously that adenovirus 5 E1A is capable of transcriptionally repressing the HER-2/neu promoter. We report here that the E1A-associated p300 protein can derepress the E1A-mediated repression of HER-2/neu in a dose-dependent manner. A p300 mutant, which lost its ability to bind to E1A, also effectively rescued the repressed HER-2/neu promoter in the presence of excess E1A inside the cells. A protein complex can bind to the p300 consensus sequences in HER-2/neu promoter. The intensity of the retarded band of the protein complex decreased significantly after preincubation of the nuclear extracts with beads that has been conjugated with anti-p300 antibody. The binding of E1A to p300 and the p300 consensus sequence in HER-2/neu promoter were crucial for the ability of E1A to repress HER-2/neu promoter, demonstrating that p300 is involved in the transcriptional regulation of HER-2/neu and serves as a target for E1A repression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045619     DOI: 10.1074/jbc.272.10.6101

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Suppression of E1A-mediated transformation by the p50E4F transcription factor.

Authors:  E R Fernandes; R J Rooney
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  Downregulation of microRNA miR-520h by E1A contributes to anticancer activity.

Authors:  Jen-Liang Su; Poshen B Chen; Ya-Huey Chen; Shang-Chih Chen; Yi-Wen Chang; Yi-Hua Jan; Xiaoyun Cheng; Michael Hsiao; Mien-Chie Hung
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 3.  Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens.

Authors:  U Moens; O M Seternes; B Johansen; O P Rekvig
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

Review 4.  The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.

Authors:  Katie Lin; Stavroula Baritaki; Silvia Vivarelli; Luca Falzone; Aurora Scalisi; Massimo Libra; Benjamin Bonavida
Journal:  Antioxidants (Basel)       Date:  2022-06-17

5.  E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway.

Authors:  Liangfang Shen; Shan Zeng; Jia Chen; Meizuo Zhong; Huixiang Yang; Ruojing Yao; Hong Shen
Journal:  Med Oncol       Date:  2007-09-28       Impact factor: 3.064

6.  Involvement of HTLV-I Tax and CREB in aneuploidy: a bioinformatics approach.

Authors:  Cynthia de la Fuente; Madhur V Gupta; Zachary Klase; Katharine Strouss; Patrick Cahan; Timothy McCaffery; Anthony Galante; Patricia Soteropoulos; Anne Pumfery; Masahiro Fujii; Fatah Kashanchi
Journal:  Retrovirology       Date:  2006-07-05       Impact factor: 4.602

7.  The adenovirus E1A oncoprotein N-terminal transcriptional repression domain enhances p300 autoacetylation and inhibits histone H3 Lys18 acetylation.

Authors:  Ling-Jun Zhao; Paul M Loewenstein; Maurice Green
Journal:  Genes Cancer       Date:  2015-01

8.  Myocyte enhancer factor-2 and p300 interact to regulate the expression of homeostatic regulator Pumilio in Drosophila.

Authors:  Wei-Hsiang Lin; Richard A Baines
Journal:  Eur J Neurosci       Date:  2019-02-21       Impact factor: 3.386

9.  Functional genetic variants of the IFN-λ3 (IL28B) gene and transcription factor interactions on its promoter.

Authors:  Subhajit Roy; Debarati Guha Roy; Anand Bhushan; Seema Bharatiya; Sreedhar Chinnaswamy
Journal:  Cytokine       Date:  2021-03-13       Impact factor: 3.861

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.